Alendronate Is Effective to Treat Bone Loss in Renal Transplantation Recipients

Transplantation Proceedings

Volumn 40, Issue 10, 2008, Pages 3496-3498

  Lan, G ^a   Peng, L ^a   Xie, X ^a   Peng, F ^a   Wang, Y ^a   Yu, S ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM CARBONATE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PREDNISONE;

ADULT; AGE; ARTICLE; BIOCHEMISTRY; BODY MASS; BONE ATROPHY; BONE DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; GENDER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CREATININE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 57549118897     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.034     Document Type: Article

References (17)

1. Nisbeth U., Lindh E., Ljunghall S., et al. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 67 (1999) 1218
2. Mikuls T.R., Julian B.A., Bartolucci A., et al. Bone mineral density changes within six months of renal transplantation. Transplantation 75 (2003) 49
3. Sperschneider H., and Stein G. Bone disease after renal transplantation. Nephrol Dial Transplant 18 (2003) 874
4. Lim S., Joung H., Shin C.S., et al. Body composition changes with age have gender-specific impacts on bone mineral density. Bone 35 (2004) 792
5. Trabulus S., Apaydin S., Altiparmak M.R., et al. Osteoporosis after renal transplantation. Nefrologia 23 (2003) 127
6. Delany A.M., Dong Y., and Canalis E. Mechanisms of glucocorticoid action in bone cells. J Cell Biochem 56 (1994) 295
7. Murphy M.G., Weiss S., McClung M., et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86 (2001) 1116
8. Downs Jr. R.W., Bell N.H., Ettinger M.P., et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85 (2000) 1783
9. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid- induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309
10. Toro J., Gentil M.A., Garcia R., et al. Alendronate in kidney transplant patients: a single-center experience. Transplant Proc 37 (2005) 1471
11. Mitterbauer C., Schwarz C., Haas M., et al. Effects of bisphosphonates on bone loss in the first year after renal transplantation-a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21 (2006) 2275
12. Haas M., Leko-Mohr Z., Roschger P., et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63 (2003) 1130
13. Torregrosa J.V., Moreno A., and Gutiérrez A. Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc 35 (2003) 1393
14. Bellorin-Font E., Rojas E., Carlini R.G., et al. Bone remodeling after renal transplantation. Kidney Int 63 (2003) S125
15. Borah B., Dufreense T.E., Chmielewski P.A., et al. Risedronate preserves trabecular architecture and increases bone strength in vertebrae of ovariectomized minipigs as measured by 3 dimensional microcomputed tomography. J Bone Miner Res 17 (2002) 1139
16. Melo M., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111
17. Pendrys D.G., and Silverman S.L. Osteonecrosis of the jaws and bisphosphonates. Curr Osteoporos Rep 6 (2008) 31